Startupticker.ch’s Post

AbbVie Inc (NYSE:ABBV)'s approximately $137.5 million acquisition of Landos Biopharma is a strategic move by the pharmaceutical research and development firm which has reiterated the potential of novel innovations with high-growth prospects in the small-cap #biotech sector. AbbVie, best known for producing rheumatoid arthritis and Crohn's Disease medication Humira, on Monday announced the deal which will bolster its portfolio of drug candidates for inflammatory and autoimmune diseases.   Landos Biopharma’s lead clinical asset is NX-13, an oral NLRX1 agonist that is in Phase 2 trials for the treatment of the inflammatory bowel disease ulcerative colitis.  For investors focused on small-cap opportunities in the biotech sector, the acquisition has underscored the allure and potential of up-and-coming biotech firms with promising therapeutic candidates. More at #Proactive #ProactiveInvestors #NASDAQ #IMUX http://ow.ly/IVw7105nqFO

🗞Richardson Round Up 🗞 2024 is off to a positive start, following a challenging year in 2023. The market is showing promising developments, with notable acquisitions and partnerships in the market. ✅ AbbVie agrees to acquire Landos Biopharma, Inc. The acquisition aims to advance the clinical development of first-in-class oral assets with the potential to make a difference in the lives of people living with ulcerative colitis and Crohn's disease. 💊 Novo Nordisk agrees to acquire Cardior Pharmaceuticals. The acquisition is part of Novo Nordisk’s strategy to establish a presence in cardiovascular disease. They aim to build a portfolio of therapies through internal and external innovation. ⏫ Bayer and Thermo Fisher Scientific partner to advance access to precision cancer medicines. This partnership is aimed to develop next-generation sequencing-based companion diagnostic assays, to help identify patients who may benefit from Bayer’s precision cancer therapies by offering decentralised genomic testing and rapid turnaround time. 📈 Lonza acquires Biologics Manufacturing site from Roche. This acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity to meet the demand for commercial mammalian contract manufacturing. Stay tunes for more updates in our space! #biologics #mammalian #contractmanufacturing #cdmo #pharmaceuticals

✨Exciting news just dropped in the biotech space!✨ Silence Therapeutics has just kickstarted a significant chapter with AstraZeneca, marking their collaborative effort sailing into Phase 1 trials for groundbreaking siRNA therapies. Whilst a $10M milestone payment has landed in Silence Therapeutics plc account, this is more than just a financial win; it's a reflection of the trust in their mRNAi GOLD™ platform's capabilities. This Phase 1 launch is a huge nod to the team's dedication and sets all off on a promising trajectory for their pivotal partnership with AstraZeneca🤝🚀 As both organizations stand at the forefront of precision medicine, It's amazing to see both teams pushing boundaries and redefining what's possible. Here's to future milestones that transform groundbreaking science into life-changing therapies! ✅💊 #SilenceTherapeutics #AstraZeneca #InnovationInMedicine #ClinicalResearch #ClinicalTrials #Biotechnology #Pharmaceuticals #LifeScience #ElixirAssociates #StaffingPartner

Some of the latest Life Science News / Updates: ➡ Veeda Clinical Research Limited acquires European CRO - Heads ➡ Novo Nordisk to acquire heart-disease focused Cardior Pharmaceuticals in deal worth $1.1 billion ➡ Gilead Sciences completes acquisition of CymaBay Therapeutics for approximately $4.3 billion ➡ AbbVie to acquire Landos Biopharma, Inc. further strengthening its portfolio in Inflammatory and Autoimmune diseases ➡ Avenzo Therapeutics raises $150M in Series A1- financing ➡ Nocion Therapeutics, Inc. has raised $62 million series B, bringing the company's total raised to $122 million since 2018 ➡ FogPharma has raised $145 million in a series E ➡ BlossomHill Therapeutics, Inc. has raised $100 million in a series B, bringing the company’s total fundraising to $173 million

CD-20 Market to Witness Significant Growth During the Study Period (2019-2032), Assesses DelveInsight | Major Players – TG Therapeutics, Genentech (Roche), Genmab, Abbvie, Regeneron #Finance #FinancialMarket #MarketingSales #PharmaceuticalsBiotech

Enjoy this eBook titled, "ADC Advances — Leveraging Classical and Emerging Technologies." Between 2000 and 2019, the US Food and Drug Administration approved only four #antibodydrugconjugate products for commercial distribution. Between then and 2024, however, the number of marketed ADC products has swelled to 13, and #clinicalstudies are underway for more than 100 candidates that address nearly 40 indications, mostly in oncology. This eBook presents interviews with two #pharmaceutical executives to survey the current ADC landscape and imagine future pathways for discovery and development activities. Read the full eBook here: https://lnkd.in/gFfJvanX

When doing research for this report on #ADCs and other #bioconjugates, I was amazed by the myriad conjugation chemistries and linker technologies that drug developers now can leverage to enhance cancer treatment. In the report, David Dornan explains how companies such as Elevation Oncology are combining classical and emerging approaches to improve drug conjugation and release. Then, Christopher Nasveschuk of C4 Therapeutics, Inc. gives insight into the future of of ADCs, describing early research into conjugating ADCs with small-molecule protein degraders for cancer treatment. Read the report to learn more! Many thanks to David and Chris for sharing their insights! https://lnkd.in/gFfJvanX

Stories making headlines today in the biopharma industry: Biotech companies, focusing on radiopharmaceuticals, neuroscience, and inflammation therapies, are being acquired for substantial premiums due to their potential to bridge gaps in the pharmaceutical field. For instance, Bristol Myers Squibb purchased radiopharmaceutical company RayzeBio at a 104% premium just three months post-IPO. Raising the bar in the oncology biotech space, Pennsylvania-based ArriVent BioPharma prepares for a $175 million IPO on Nasdaq with its furmonertinib, an EGFR-targeted tyrosine kinase inhibitor, being its lead asset. Venture capital player Innovation Endeavors, co-founded by ex-Google CEO Eric Schmidt, has launched a new $630 million fund. A significant portion of this fund will invest in life sciences and healthcare, indicating the firm's increasing focus on biotech. Merck's cancer prevention drug, Keytruda, demonstrates a 31% reduction in the risk of bladder cancer recurrence or death post-surgery. Despite not achieving its expected survival endpoint, the interim analysis data shows promise. In other news, Deerfield exits a 2017 deal with Windtree Therapeutics, while Travere Therapeutics finalizes a new $120 million deal with Renalys Pharma. Additionally, Celularity raised $21 million, and Sagimet Biosciences plans for a $112.5 million public offering. Moving towards pipeline development, Strand Therapeutics scales back its workforce by 18%. However, stay optimistic as CEO Jacob Becraft assures the firm’s robust financial runway. Navigating through challenges in 2023, Lonza remains hopeful about revenue growth this year along with plans to shutter its second biologics site soon. Personal updates reveal Bayer's radiology head planning retirement and ex-Sanofi chief Olivier Brandicourt joining BeiGene’s board. After facing a dip in VC and financing in 2023, the UK's life sciences sector now seems primed for an upward trajectory. #pharma #biotech #topstories #biodatastudio

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Genentech ends SHP2 deal with Relay Therapeutics after other pharma exits: Roche’s Genentech is scrapping a collaboration and license agreement with Relay Therapeutics surrounding the biotech’s clinical-stage oral SHP2 inhibitor. It’s the latest pharmaceutical company to renege on a SHP2 partnership in oncology. Bristol Myers Squibb departed a pact with BridgeBio earlier this year, AbbVie did the same with Jacobio Pharma in 2023 and Sanofi left Revolution Medicines in 2022. Merck, meanwhile, continues to have a SHP2 deal in place with Taiho and Astex. Genentech “elected to terminate the agreement without cause,” Cambridge, MA-based Relay disclosed in a Tuesday post-market SEC filing. As part of their 2020 deal, Genentech had assumed development of the oral small molecule, dubbed GDC-1971/RLY-1971 or migoprotafib. The decision was “not based on any emerging clinical safety concerns,” a Genentech spokesperson said in an emailed statement to Endpoints News. The drug went through a monotherapy study a few years ago and is in a couple of Phase 1 trials in combination with other drugs. The pair had broad ambitions for the SHP2 inhibitor across multiple solid tumor types, including as a combination partner for Genentech’s KRAS G12C candidate known as GDC-6036 or divarasib. “Genentech is committed to ensuring that patients being treated with GDC-1971 in clinical trials continue to have access,” the Genentech spokesperson said. “All patients enrolled in a trial involving GDC-1971 or combinations thereof will continue to receive study treatment as long as they meet study criteria and they and their physician agree to continue.” Relay received $75 million upfront to kick off the collaboration in late 2020. Genentech has paid about another $45 million in biobucks and R&D reimbursements since then, according to Relay’s SEC paperwork on Tuesday. Under the original pact, Relay could have received up to $695 million in milestone payments. Roche, the parent of Genentech, has broadly fine-tuned its pipeline in the past year. Genentech itself broke off a T cell therapy tie-up with Adaptimmune earlier this year, and is also reducing about 3% of its workforce, the company told Endpoints in April. “We’ve taken out 20% of our molecules that have a lower likelihood to succeed, and we’ve added new ones through partnering,” Roche CEO Thomas Schinecker said on a first-quarter earnings call with the media in April. It’s part of normal business to prioritize and “constantly reallocate,” he added. Relay doesn’t plan to make any workforce changes as a result of the axed deal, given Genentech was the one responsible for the experimental medicine’s development, a spokesperson for the biotech told Endpoints. #lucidquest #genetherapy #celltherapy

In first biotech IPO of the year, CG Oncology overshoots estimates by bringing in $380M >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #competitivemarketing #biotech